Showing results (31-40 of 45) with videos related to
Sort By:
Pageof 5
Journal of Clinical Pharmacology|December 6, 2019
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)Manish R Sharma, Shailly Mehrotra, Elizabeth Gray, et al.European Journal of Cancer (Oxford, England : 1990)|May 22, 2026
Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumorsKyriakos P Papadopoulos, Manish R Sharma, Reinhard Dummer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid TumorsMichael L Maitland, Jasgit C Sachdev, Manish R Sharma, et al.Journal for Immunotherapy of Cancer|March 8, 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumorsNikhil I Khushalani, Patrick A Ott, Robert L Ferris, et al.Cell Reports. Medicine|December 30, 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART MoleculeAlexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, et al.Clinical Therapeutics|February 29, 2024
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid TumorsGerald Falchook, Amita Patnaik, Debra L Richardson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction CancerJohn H Strickler, Judith Raimbourg, Jonathan E Cohen, et al.Cancer Research Communications|January 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.Cancer Research Communications|February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2018
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid TumorsJason J Luke, Jeffrey M Lemons, Theodore G Karrison, et al.Pageof 5